Member Info for GETINTHERE

Troajan

The 2nd quarter will I’m sure be better than the first, but not by any awe inspiring amount as they have only been processing low and medium grade and won’t get to mine let alone process the high level stuff until next week which is the last week of the quarter.

Q3 will be the litmus test in terms of production levels from the high level areas and Q4 when we are due to finally move on to 7 day production will hopefully prove that the production targets are achievable.

Time will tell, but things are improving and the future is looking brighter ;-)

I made a post earlier today with the same heading, it has been inexplicably deleted ?

There was absolutely nothing in the post that was against the LSE rules so I don’t understand it, unless someone else posted something on the same thread and that was reported and the whole thread deleted ?

I only reiterated that I had loads of green boxes (this is because I’ve filtered people who in my opinion are not investors but simply trouble makers) and that I ignore them because what matters is that WRES will be producing from the high grade areas within days - these are facts and are relevant to this discussion board !

Oh well never mind the facts remain the facts WRES will be producing from the high grade areas within days - as per today’s RNS from the company and I do have and will keep numerous posters filtered because I don’t believe that they add anything meaningful to the board.

If this post is reported and in the unlikely event that it gets deleted - ADMIN can you please explain which rule my post breaches as I do not understand?

SNG will succeed we just have to wait patiently that’s all, patience is the key

MIB

I can’t argue with that ;-)

However whatever today’s close is, tomorrow’s close will be determined by an RNS, or, lack of one.

Schrow

Google normally shows the uncrossing trade at 4.35 it came up as £1.749, but subsequently the mid market closing price was and is showing as £1.80

And that’s before we get confirmation via an RNS, before we get (hopefully) an EUA, before we get the results from the P3 trial, before we have sold one single dose, and before we have been looked at as a major takeover target by what will no doubt be several large pharmaceutical companies.

The next 3-6 months here are going to be very interesting and hopefully very rewarding ;-)

What sells ? There was a large uncrossing trade and one late reportedly 10,000 share trade buyback that’s all !

Patience is the key here, I’ve been patient for a long time, so another few months makes no difference to me.

Everything comes to he who waits ;-)

In this case everything being full production or at least close to it and the then inevitable re-rate ;-)

Good morning Tonlin,

I’m always up and about well before 6am mate, I seem to sleep less as I get older mate.

I trust you are fit and well ?

The French health minister would hardly have stated that Synairgen had a patent if the french were going to challenge that patent or try to ignore that patent.

Talk of the french overriding the patent is pure scaremongering, nothing more.

And of course as I’ve already pointed out, they are using 1b which’s less effective and we are using 1a

Further facts - Synairgens treatment is not only more advanced it is also different, and more effective:-

The more direct approach of pulmonary IFN-ß nebulization is presently explored by Wilkinson et al. in collaboration with Synairgen, in a clinical trial with SNG001, a nebulizable form of IFN-ß-1a (NCT04385095). However, these approaches are moving toward patent-protected products, with limited supply. A main advantage of IFN-ß-1b is its immediate supply as a biosimilar, with a formulation suitable for nebulization without the need of major modifications. IFN-ß-1b differs from IFN-ß-1a in the way it is produced. On the one hand, IFN-ß-1b is synthesized by bacteria without glycosylation and with modifications of 2 amino-acids to maintain stability. IFN-ß-1a, on the other hand, is produced by mammalian cells and has a structure identical to natural IFN-ß. Their difference results in a decrease of pharmacodynamic activity of about 25% for IFN-ß-1b, as compared to IFN-ß-1a. The decreased activity is compensated by a higher dosage of IFN-ß-1b per vial (Stürzebecher et al., 1999).

Fact :-

The only complete, currently available Treatment Emergent Adverse Events (TEAE) study with IFN-ß inhalation comes from Synairgen, a drug discovery and development company founded by the University of Southampton, United Kingdom who developed SNG001, an aerosolizable form of IFN-ß-1a. SNG001 has been used in phase 1 and 2 clinical trials with the aim to reduce rhinovirus-related symptoms in asthma patients. The drug allowed limited use of corticosteroids and presented few side effects (limited to 6.9% heart palpitations) (Djukanovic et al., 2014). Moreover, no fever was observed although it was found in almost half of the patients when the product was administered subcutaneously (Limmroth et al., 2011). Psychiatric side effects were limited to rare sleep disturbances, and there was no significant hematological or hepatic toxicity, consistent with poor systemic passage of IFN aerosols (Djukanovic et al., 2014). In view of this favorable risk/benefit balance, we decided to develop a nebulization protocol for IFN-ß-1b administration. We present here the methods of IFN-ß-1b administration, and the results obtained in four patients after administration on a compassionate basis.

Bdog

Yes mate things are, FINALLY, looking positive - despite the negativity posted by some on here day in and day out, week in and week out, month in and month out.

Bdog

What salary is he paid ? My understanding is that he doesn’t receive any salary, do you know something different ? If so please explain where his salary is disclosed in the annual report, because I’ve obviously missed it ?

Outlook

2020 was a very difficult year for the Company and the world at large with the Covid-19 pandemic, however, as we continue to prioritise our efforts at the La Parrilla mine steps taken last year should begin to feed through in H2 2021 as we:
· Look to permanently solve our water issue and re-access our higher-grade ore bodies
· Produce between 880t and 1,000t of concentrate for the twelve months ending 31 December 2021
· Move production at La Parrilla mine back to a 24/7 basis and get close to a T2 run-rate in Q4 2021
· At our earliest opportunity, re-commence mining activities at our tungsten mine in Régua, Portugal
· Move to an initial breakeven period and then migrate to a profit generating company as we see positive operational cashflow and a turnaround in shareholder value.
The management team with the strong support of the board continue to progress the Company's plan of reaching T2 as well as keeping its staff and contractors safe and well in these troubling times.

Troajan

Agreed, but maybe they will soften the blow with some good figures for the month of May ;-)

It’s overdue based on last years timing, and Friday is a good day for what will surely be bad news -:(

I think that most long term holders new that, but not knowing doesn’t make you or anyone else thick mate, you know now ;-)

Tonlin,

All is well here too mate, (other than the SP of course) but we will get there - eventually !

Have a great day ;-)